<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

5 min read

What Impact will GLP-1 Agonists have on Chronic Wounds?

3/5/24 2:24 PM

GLP-1 JEADER copyWith many believing that GLP-1 agonists should be considered a “wonder drug,” SmartTRAK explores what impact their use could have on the market for wound care.

SmartTRAK estimates that there were 77.7MM chronic wounds worldwide (US, Europe, Japan, Australia, Canada, Brazil, China and India) in 2022, of which 41.4MM were hard-to-heal. Wound numbers are forecast to grow at a five-year CAGR of +0.8%, which is higher than the forecasted population growth of +0.3% but below the growth of those aged over 65 years old.
In this article, SmartTRAK provides an overview of GLP-1 agonists, explores the possible impact these drugs will have on the conditions that drive wound prevalence and advises on how the outcomes will influence future estimates.
Among the topics covered in this article are:
  • What are GLP-1 Agonists?
    GLP-1 agonists are a class of drugs mimicking the action of a hormone called glucagon-like peptide 1. The drugs stimulate glucose-dependent insulin release from the pancreas. A range of agonists have been developed and launched, with the first product being ... (read more)

  • What is the Future for GLP-1 Agonists?
    Financial indicators suggest that GLP-1 agonists are expected to expand significantly in use around the world. The two companies with drugs licensed for weight loss have seen record share price growth are ... (read more)

  • What Impact Are GLP-1 Agonists Expected to Have on Diabetes and Obesity?
    When GLP-1 agonists were launched in 2005, they required twice daily injections. This was driven by the rapid elimination, or short half-life, of the compounds. With further development, companies have improved usability and weekly injections and ... (read more)

  • How will GLP-1 Agonists Impact SmartTRAK Forecast for Wound Prevalence?
    SmartTRAK estimates wound numbers by type for the most recent full year and forecasts five years into the future. These estimates and forecasts are ... (read more)

In recent years, there has been a significant increase in published research into the weight-loss effect of GLP-1 agonists in both diabetic and non-diabetic patients. A 2023 systematic review with meta-analysis showed that GLP-1 agonists significantly reduced body weight (11.7lb mean difference), body mass index (2.4kg/m2) and waist circumference (1.7 inches) in non-diabetic obese or overweight patients. These results, alongside a wave of celebrities and influencers actively promoting the beneficial effects of the products, have led to ...

To download and read the complete "What Impact will GLP-1 Agonists have on Chronic Wounds?" article by Kris Flinn, SmartTRAK Senior Analyst - Wound, just click the button below.Read the Article

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK offers and how we can help increase proficiency, improve productivity and reduce costs for your company, just click here

Kris Flinn
Written by Kris Flinn

Analyst, Wound Care - 20+ years of experience within wound care including Smith & Nephew. Recently ran a consultancy focusing on assisting med device companies with commercial strategies. Kris is based in England.

  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles